PF-Atlas › Исследования › AI Discovery
Исследования: AI Discovery (27)
27 публикаций в теме «AI Discovery», проиндексированных PF-Atlas из PubMed и мировых журналов.
- Innovative strategies for anti-fibrotic drugs discovery from traditional Chinese medicine. · Chinese herbal medicines · 2026
- An Integrated Machine-Learning and Reverse Network-Pharmacology Pipeline Reveals JUN/C3 Candidate Biomarkers and an Anti-Fibrotic Mechanism of Resveratrol via MAPK/JNK Signaling in Chronic Kidney Disease. · International journal of molecular sciences · 2026
- Artificial intelligence in idiopathic pulmonary fibrosis: advances, challenges and future directions. · The European respiratory journal · 2026
- AlphaDTA: integrating AlphaFold3 embeddings and 3D complex structures for drug-target binding affinity prediction. · Journal of cheminformatics · 2026
- Integrated network pharmacology and bioinformatics analysis reveals MME as key target of Notoginsenoside R1 in diabetic nephropathy. · BMC complementary medicine and therapies · 2026
- Clinical AI-assisted FXR prioritization and WADDAICA-guided design of a berberine-inspired analogue for MASH: integrated computational and experimental validation. · Frontiers in pharmacology · 2026
- Network Pharmacology, Machine Learning, and In Vivo Validation of Danzhi Jiangtang Capsule in Diabetic Nephropathy. · Journal of visualized experiments : JoVE · 2026
- Intestinal flagellin drives multisystem inflammation through TLR5-IL-15-ARA axis. · Gut · 2026
- Natural Products Targeting Airway Inflammation and Mucus Hypersecretion: Molecular Mechanisms and Therapeutic Potential for Respiratory Health. · Nutrients · 2026
- Targeting the CD4 effector memory T cells re-expressing CD45RA suppressor galectin-7: a multi-omics-guided therapeutic strategy for idiopathic pulmonary fibrosis. · Molecular biomedicine · 2026
- Multi-omics and AI-guided discovery and validation of sisomicin as a COPA-targeting agent for pathological scar inhibition. · Burns : journal of the International Society for Burn Injuries · 2026
- Inhibiting RhoA Activation Via GDP-State Stabilization to Relieve Heart Failure. · Circulation research · 2026
- Natural language processing of biomedical text to map and prioritize protein-disease associations in HFpEF. · Computers in biology and medicine · 2026
- Microfluidic innovations in chronic kidney disease and renal fibrosis: from mechanistic insights to clinical applications. · Frontiers in medicine · 2026
- Design of RGD-functionalized GSH-responsive pegylated polymeric protacs for selective BRD4 degradation and EndMT-driven cardiac fibrosis inhibition. · Journal of nanobiotechnology · 2026
- Machine learning and network pharmacology identify keloid biomarkers and therapeutic targets for aloe-derived quercetin. · PloS one · 2026
- Leading artificial intelligence-driven drug discovery platforms: 2025 landscape and global outlook. · Pharmacological reviews · 2026
- Chimeric Antigen Receptor T Cells as Living Therapeutics Targeting Senescence and Age-Related Diseases. · Research (Washington, D.C.) · 2026
- A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial · Nature Medicine · 2025
- Artificial Intelligence-Driven Discovery of Pyrazolo[1,5-a]pyrimidine Derivatives as Novel Phosphodiesterase 4 Inhibitors for Treating Idiopathic Pulmonary Fibrosis. · Journal of medicinal chemistry · 2025
- Multi-omics and machine learning identify FN1 and ALDH2 as diagnostic biomarkers and therapeutic targets in early and late diabetic kidney disease. · Renal failure · 2025
- Identification of hub necroptosis-related targets and discovery of potential natural inhibitors in ulcerative colitis based on bioinformatics and computer-aided drug design. · Journal of computer-aided molecular design · 2025
- Serum vesicle biomarkers reflect the disease activity of idiopathic pulmonary fibrosis. · Journal of translational medicine · 2025
- Integrated Machine Learning and Structure-Based Virtual Screening Identify Osimertinib as a TNIK Inhibitor for Idiopathic Pulmonary Fibrosis. · Journal of chemical information and modeling · 2025
- Integrating Network Pharmacology, Machine Learning, and Experimental Validation to Elucidate the Mechanism of Cardamonin in Treating Idiopathic Pulmonary Fibrosis. · International journal of molecular sciences · 2025
- Recent Updates on Molecular and Physical Therapies for Organ Fibrosis. · Molecules (Basel, Switzerland) · 2025
- Resveratrol attenuates pulmonary fibrosis by inhibiting alveolar epithelial senescence via targeting SASP-related proteins: an integrated bioinformatics-experimental study. · Frontiers in pharmacology · 2025
Медицинская оговорка. Списки исследований приведены только для информации и не являются медицинской рекомендацией.